Tinuvin 770: used as a light stabilizer for polyolefins; an L-type Ca2+ channel blocker; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 164282 |
| CHEMBL ID | 1871877 |
| SCHEMBL ID | 30741 |
| MeSH ID | M0222726 |
| Synonym |
|---|
| bis(2,2,6,6-tetramethyl-4-piperidinyl) sebacate |
| tinuvin 770df |
| hals 770 |
| tk-10665 |
| ls 770 |
| hals 1 |
| sanol 770 |
| tin 770 |
| sanol |
| bis(2,2,6,6-tetramethyl-4-piperidyl)sebacate |
| sumisorb 577 |
| tinuvin 770 |
| mark la 77 |
| bis(2,2,6,6-tetramethyl-4-piperidinyl) decanedioate |
| einecs 258-207-9 |
| bis(2,2,6,6-tetramethyl-4-piperidinyl)sebacate |
| sanol ls 770 |
| sanol ls 700 |
| adk stab la 77 |
| c28h52n2o4 |
| t 770 |
| tinuvin 770ls |
| bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate |
| NCGC00164198-01 |
| decanedioic acid, bis(2,2,6,6-tetramethyl-4-piperidinyl) ester |
| 52829-07-9 |
| bis(2,2,6,6-tetramethylpiperidin-4-yl) sebacate |
| AC-2008 |
| AKOS001482497 |
| sebacic acid bis(2,2,6,6-tetramethyl-4-piperidyl) ester |
| decanedioic acid bis(2,2,6,6-tetramethyl-4-piperidyl) ester |
| S0448 |
| STK669933 |
| bis(2,2,6,6-tetramethylpiperidin-4-yl) decanedioate |
| tox21_202763 |
| dtxcid708030 |
| dtxsid0028030 , |
| NCGC00260310-01 |
| cas-52829-07-9 |
| bis-(2,2,6,6-tetramethylpiperidin-4-yl) sebacate |
| bis(2,2,6,6-tetramethylpiperdin-4-yl) sebacate |
| bis(2,2,6,6-tetramethylpiperid-4-yl) sebacate |
| di-(2,2,6,6-tetramethylpiperidin-4-yl) sebacate |
| bis(2,2,6,6-tetramethylpiperidin-4-yl)sebacate |
| bis(2,2,6,6,-tetramethyl-4-piperidyl)sebacate |
| unii-6803a71201 |
| hillite 77 |
| adeka la 77 |
| gw 480 |
| ec 258-207-9 |
| 6803a71201 , |
| eversorb 90 |
| tn 770 |
| decanedioic acid, 1,10-bis(2,2,6,6-tetramethyl-4-piperidinyl) ester |
| antioxidant 770 |
| viosorb 04 |
| uvinul 4077h |
| FT-0622984 |
| decanedioic acid, 1,10-bis(2,2,6,6-tetramethyl-4- piperidinyl) ester |
| AB01322330-02 |
| SCHEMBL30741 |
| MS-0925 |
| bis-(2,2,6,6-tetramethyl-4-piperidyl) sebacate |
| W-105793 |
| CHEMBL1871877 |
| lowilite 77 |
| uvaseb 770 |
| uv-770 |
| mfcd00134709 |
| tinuvin770 |
| NCGC00164198-02 |
| Q15632726 |
| A929217 |
| sebacic acid, bis(2,2,6,6-tetramethyl-4-piperidinyl) ester |
| bis(2,2,6,6-tetramethylpiperidin-4-yl)decanedioate |
| CCA82907 |
| CS-W013829 |
| F87442 |
Tinuvin 770 (BTMPS) is a non-competitive, use-dependent antagonist of nicotinic acetylcholine receptors (nAChRs) It is a biologically active component of polypropylene tubes.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tinuvin 770 is a light stabilizer present in numerous polymers utilized in medical or pharmaceutical applications (e.g., manufacturing, packaging, delivery systems and devices). " | ( Development and validation of an HPLC-MS-MS method for quantitating bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate (Tinuvin 770) and a related substance in aqueous extracts of plastic materials. Garber, MJ; Gill, M; Hua, Y; Jenke, D, 2010) | 2.01 |
| "Tinuvin 770 (BTMPS) is a non-competitive, use-dependent antagonist of nicotinic acetylcholine receptors (nAChRs). " | ( Functional central nicotinic acetylcholine receptor antagonism by systemic administration of Tinuvin 770 (BTMPS). Buccafusco, JJ; Graham, JH; Papke, RL, 2005) | 1.99 |
| "Tinuvin 770 is a biologically active component of polypropylene tubes." | ( A light stabilizer Tinuvin 770-induced toxic injury of adult rat cardiac myocytes. Benkõ, T; Járay, J; Keller , E; Kovács, A; Nemes, B; Rajs, I; Sótonyi, P; Tolokán, A, 2001) | 1.36 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tinuvin 770 not only displays L-type Ca2+ channel blocking properties, but can also lead to catecholamine release, similar to effects of the first generation of L-type Ca2+ channel blockers." | ( Comparative study on cardiotoxic effect of Tinuvin 770: a light stabilizer of medical plastics in rat model. Hubay, M; Járay, J; Kovács, A; Merkely, B; Soós, P; Sótonyi, P; Szentmáriay, I; Zima, E, 2004) | 1.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Our previous experiments have proved the toxic effects of Tinuvin 770 on isolated rat cardiomyocytes." | ( Comparative study on cardiotoxic effect of Tinuvin 770: a light stabilizer of medical plastics in rat model. Hubay, M; Járay, J; Kovács, A; Merkely, B; Soós, P; Sótonyi, P; Szentmáriay, I; Zima, E, 2004) | 0.83 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 7.4448 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 9.4547 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 7.5101 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.5012 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 5.9136 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 4.6973 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (42.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (5.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (5.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||